Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Medications to Manage Hypoglycemia (when combined) on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond

By
Published Updated Last reviewed
2 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Label's step at initiation / consider reducing the insulin or sulfonylurea dose [1]
  • Monotherapy, 70 mg/dL or lower / 0% placebo, 1.6% on 0.5 mg, 3.8% on 1 mg [1]
  • Monotherapy, severe / 0% in all arms [1]
  • Added to basal insulin, 70 mg/dL or lower / 15.2% placebo, 16.7% on 0.5 mg, 29.8% on 1 mg [1]
  • Added to basal insulin, severe / 0%, 0%, 1.5% [1]
  • Sulfonylurea combination / label says hypoglycemia was more frequent [1]
  • Ozempic with insulin / separate injections, never mixed [1]

What does the label say about the insulin or sulfonylurea combination?

The label states that patients receiving Ozempic with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia, including severe hypoglycemia [1]. When Ozempic is initiated, the label says to consider reducing the dose of the concomitant insulin secretagogue or insulin to reduce the risk of hypoglycemia, and it tells prescribers to inform patients on these medicines about the risk and the signs and symptoms of hypoglycemia. It does not give a specific amount for the reduction [1].

The label also notes that hypoglycemia was more frequent when Ozempic was used in combination with a sulfonylurea [1].

How often do lows occur on Ozempic alone?

In the 30-week trial of Ozempic alone, severe hypoglycemia occurred in none of the 129 people on placebo, 127 on 0.5 mg or 130 on 1 mg [1]. Documented symptomatic hypoglycemia at a glucose threshold of 70 mg/dL or lower occurred in 0% on placebo, 1.6% on 0.5 mg and 3.8% on 1 mg [1]. The label defines severe hypoglycemia as episodes requiring the assistance of another person [1].

A 2025 meta-analysis of 10 randomized trials of long-acting GLP-1 receptor agonists in type 2 diabetes (71,351 people) reported no increased risk of severe hypoglycemia [2].

How often did lows occur when Ozempic was added to basal insulin?

A second 30-week trial added Ozempic to basal insulin with or without metformin: 132 patients on placebo, 132 on 0.5 mg and 131 on 1 mg [1]. Documented symptomatic hypoglycemia at 70 mg/dL or lower occurred in 15.2% on placebo, 16.7% on 0.5 mg and 29.8% on 1 mg; severe hypoglycemia in 0%, 0% and 1.5%; and the combined category of severe or blood-glucose-confirmed symptomatic hypoglycemia at 56 mg/dL or lower in 5.3%, 8.3% and 10.7% [1].

The placebo group was also taking basal insulin and had a 15.2% documented symptomatic rate [1].

Giving Ozempic alongside insulin

When Ozempic is used with insulin, the label says to give them as separate injections and never to mix them; injecting in the same body region is acceptable, but the injections should not be adjacent [1].

Frequently asked questions

Does Ozempic cause low blood sugar on its own?
In the label's 30-week monotherapy trial, severe hypoglycemia occurred in 0% of the placebo, 0.5 mg and 1 mg arms, and documented symptomatic hypoglycemia at 70 mg/dL or lower occurred in 0% on placebo, 1.6% on 0.5 mg and 3.8% on 1 mg [1].
What does the label tell prescribers to explain to patients on insulin or a sulfonylurea?
It says to inform patients using these medicines about the risk of hypoglycemia and to educate them on its signs and symptoms [1].
Can Ozempic and insulin be mixed in the same injection?
No. The label says to give them as separate injections and never to mix them; the same body region is acceptable, but the injections should not be adjacent [1].
What counts as severe hypoglycemia in the Ozempic label?
An episode requiring the assistance of another person. It occurred in 0% of all arms in the monotherapy trial, and in 0% of placebo, 0% of 0.5 mg and 1.5% of 1 mg in the trial that added Ozempic to basal insulin [1].
What happened when Ozempic was added to basal insulin?
In the 30-week trial, documented symptomatic hypoglycemia at 70 mg/dL or lower occurred in 15.2% of people taking basal insulin plus placebo and 29.8% of those taking basal insulin plus Ozempic 1 mg. The label also states that hypoglycemia was more frequent when Ozempic was used with a sulfonylurea [1].

References

  1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
  2. Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. 2025;48(5):846-859. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials
Evidence overview for Medications to Manage Hypoglycemia (when combined) on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond